ESMO20: amivantamab in combination with lazertinib may be a promising option for NSCLC

The interim results from the CHRYSALIS study (NCT02609776) have been announced at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 (19–21 September). The study is an open-label, global, multicenter study investigating amivantamab in combination with lazertinib in patients with non-small-cell lung cancer (NSCLC) with EGFR exon 19 deletions or L858R mutations. Investigators assessed overall efficacy using overall response rate (ORR) defined by the RECIST v1.1 criteria, clinical benefit rate, duration of response and the safety profile of the combination. A total of 91 patients were included and treated with amivantamab–lazertinib across different cohorts. Within the 91 patients, 26...